News for Adverum Biotechnologies, Inc. (0HA3.L)

Adverum Biotechnologies (ADVM) has been the subject of a recent analyst report from RBC Capital. Analyst Luca Issi has maintained the "Sector Perform" rating on

In a recent update, Adverum Biotechnologies (ADVM) has received a maintained "Buy" rating from Chardan Capital. Lead analyst Daniil Gataulin reaffirmed the comp

RBC Capital has adjusted its price target for Adverum Biotechnologies (ADVM), lowering it from $5 to $4 while maintaining a Sector Perform rating. The revision

On May 15, 2025, HC Wainwright & Co. reaffirmed their 'Buy' rating for Adverum Biotechnologies (ADVM). The company's current analyst Matthew Caufield maintained

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or th

PR NewswireNEW YORK, May 6, 2025 NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnolo

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or the

**media[613191]**

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or

**media[595473]**

PR NewswireNEW YORK, April 14, 2025 NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotec

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Bi

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or t

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM) today announced that the Compensation Committee of Adverum's Bo

**media[586383]**

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision ou

**media[556087]**